Abstract
Several studies utilize gene therapy technology to study the molecular mechanisms and therapeutic approaches to a variety of neurological diseases. Although gene therapy for neuro-oncology and neurodegenerative diseases has advanced to the clinical arena, those of cerebrovascular nature have remained in the experimental stage and demonstrate promising results. Before gene therapy in cerebrovascular disorders can be successful, various obstacles need to be addressed. In this review, we focus on the fundamentals of gene therapy adapted to cerebrovascular diseases, which include cerebral ischemia, post-subarachnoid hemorrhagic vasospasm, arteriovenous malformations, etc. We discuss: 1) the utilization of gene delivery vehicle, through viral, non-viral, or cellular vectors; 2) the routes and specific delivery of the vector to its target cells or tissue in the central nervous system; 3) the studies that have utilized in vivo and ex vivo gene delivery approaches and their success in the attenuation of cerebrovascular injuries; and finally 4) the future of gene therapy in this field.
Keywords: Adeno-associated virus, adenovirus, herpes simplex virus, ischemia, stroke, vasospasm
Current Gene Therapy
Title: Gene Therapy in Cerebrovascular Diseases
Volume: 7 Issue: 6
Author(s): Rodney Allanigue Gabriel and Guo-Yuan Yang
Affiliation:
Keywords: Adeno-associated virus, adenovirus, herpes simplex virus, ischemia, stroke, vasospasm
Abstract: Several studies utilize gene therapy technology to study the molecular mechanisms and therapeutic approaches to a variety of neurological diseases. Although gene therapy for neuro-oncology and neurodegenerative diseases has advanced to the clinical arena, those of cerebrovascular nature have remained in the experimental stage and demonstrate promising results. Before gene therapy in cerebrovascular disorders can be successful, various obstacles need to be addressed. In this review, we focus on the fundamentals of gene therapy adapted to cerebrovascular diseases, which include cerebral ischemia, post-subarachnoid hemorrhagic vasospasm, arteriovenous malformations, etc. We discuss: 1) the utilization of gene delivery vehicle, through viral, non-viral, or cellular vectors; 2) the routes and specific delivery of the vector to its target cells or tissue in the central nervous system; 3) the studies that have utilized in vivo and ex vivo gene delivery approaches and their success in the attenuation of cerebrovascular injuries; and finally 4) the future of gene therapy in this field.
Export Options
About this article
Cite this article as:
Gabriel Allanigue Rodney and Yang Guo-Yuan, Gene Therapy in Cerebrovascular Diseases, Current Gene Therapy 2007; 7 (6) . https://dx.doi.org/10.2174/156652307782793496
DOI https://dx.doi.org/10.2174/156652307782793496 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Meet Our Section Editor
Central Nervous System Agents in Medicinal Chemistry Contribution of Mast Cells to Cerebral Aneurysm Formation
Current Neurovascular Research Cerebroprotective Functions of HO-2
Current Pharmaceutical Design Endovascular Treatment of Pulmonary and Cerebral Arteriovenous Malformations in Patients Affected by Hereditary Haemorrhagic Teleangiectasia
Current Pharmaceutical Design Benign Intracranial Lesions - Radiotherapy: An Overview of Treatment Options, Indications and Therapeutic Results
Reviews on Recent Clinical Trials Vasculogenesis: Making Pipes for the Cardiovascular Plumbing
Current Angiogenesis (Discontinued) Antiepileptic Treatment Strategy in Vascular Malformations
Current Pharmaceutical Design Persistent Pulmonary Hypertension of the Newborn: Therapeutical Approach
Mini-Reviews in Medicinal Chemistry Cerebral Amyloid Angiopathy-related Intracerebral Hemorrhage Score For Predicting Outcome
Current Neurovascular Research Prevention of Intracerebral Haemorrhage
Current Drug Targets TGF-β Receptor Signaling Pathways in Angiogenesis; Emerging Targets for Anti-Angiogenesis Therapy
Current Pharmaceutical Biotechnology bmp3 is Required for Integrity of Blood Brain Barrier by Promoting Pericyte Coverage in Zebrafish Embryos
Current Molecular Medicine Increased Radioisotope Accumulation Around Pulmonary Arteriovenous Fistula Illustrated by Tc-99m-macroaggregated Albumin Scintigraphy and SPECT/CT in a Patient with Osler-Weber-Rendu Syndrome
Current Medical Imaging Epidemiology, Prognosis and Prevention of Non-Traumatic Intracerebral Hemorrhage
Current Pharmaceutical Design Antiplatelet Therapy And Percutaneous Coronary Interventions
Current Cardiology Reviews Solving the Blood-Brain Barrier Challenge for the Effective Treatment of HIV Replication in the Central Nervous System
Current Pharmaceutical Design Diagnosis and Management of Heart Failure with Preserved Ejection Fraction: 10 Key Lessons
Current Cardiology Reviews Ablation of T-Helper 1 Cell Derived Cytokines and of Monocyte-Derived Tumor Necrosis Factor-α in Hereditary Hemorrhagic Telangiectasia: Immunological Consequences and Clinical Considerations
Current Pharmaceutical Design PDE4D Gene in the STRK1 Region on 5q12: Susceptibility Gene for Ischemic Stroke
Current Medicinal Chemistry Hereditary Haemorrhagic Telangiectasia (HHT): Genetic and Molecular Aspects
Current Pharmaceutical Design